Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
Authors:
- Samuel Díaz InsaSISamuel Díaz Insa
- Ángel GuerreroÁGÁngel Guerrero
- Javier VigueraJVJavier Viguera
- Vicente Medrano MartínezVMVicente Medrano Martínez
- Carlos Calle de MiguelCMCarlos Calle de Miguel
- Jesús Porta-EtessamJPJesús Porta-Etessam
- Antonio CiudadACAntonio Ciudad
- Silvia Diaz-CerezoSDSilvia Diaz-Cerezo
- Ana Roncero MartínAMAna Roncero Martín
- Mercedes NúñezMNMercedes Núñez
Open Access
- 28 March 2024
- journal article
- research article
- Published by Springer Nature in Pain and Therapy
- Vol. 13 (3) , 557-576
Abstract
Introduction The efficacy of galcanezumab has been demonstrated in randomized controlled trials, but evidence about its use under clinical practice conditions is still limited. This study aimed to describe the characteristics of the patients treated with galcanezumab in routine clinical practice in Spain as well as treatment patterns, persistence, and effectiveness. Methods A retrospective chart review study was carried out in six hospitals. Information of adults with migraine, who started treatment with galcanezumab between November 2019 and September 2021, was analyzed until end or loss of follow-up. Continuous variables were described as mean (standard deviation, SD) and median (interquartile range, IQR), and categorical variables as frequency and percentages. Persistence to treatment was estimated using Kaplan–Meier analysis. Results A total of 314 patients were analyzed over median follow-up period of 17.5 months (13.8–20.7), with a mean age of 46.3 (12.6), 85% women, 80.6% chronic migraine, and reporting a mean of monthly migraine days of 16.7 (7.8). Overall, 72.9% had comorbid conditions, with anxiety and depression disorders being the most frequent. More than 60% had received ≥ 6 previous preventive drugs, the most common being antiepileptics, antidepressants, and botulinum toxin (95.2%, 89.8% and 84.1%, respectively). Overall, 60.3% of the patients with other preventive treatments maintained them after galcanezumab initiation. The median time on galcanezumab was 14.6 months (9.4–22.8); 95.7%, 82.0%, 76.2% and 59.8% of patients were persistent to treatment at 3, 6, 9 and 12 months, respectively. Of the patients who discontinued (151: 48.1%), 57.6% were due to lack of effectiveness and 31.1% were due to improvement in migraine. The average reduction of monthly migraine days at 3, 6, 9 and 12 months was 7.9 (7.2), 9.1 (7.5), 8.8 (6.6) and 9.0 (6.9) days, respectively. Conclusions In real clinical practice, galcanezumab is an effective treatment and has a high persistence in patients with migraine, mostly chronic and with multiple use of previous preventive treatments.Keywords
Funding Information
- Eli Lilly and Company
This publication has 35 references indexed in Scilit:
- Global epidemiology of migraine and its implications for public health and health policyNature Reviews Neurology, 2023
- Real life experience of one year treatment with Galcanezumab in chronic migraine with and without medication overuse headacheJournal of the Neurological Sciences, 2021
- Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER TrialAdvances in Therapy, 2021
- Migraine: epidemiology and systems of careThe Lancet, 2021
- Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine preventionRevue Neurologique, 2020
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trialThe Lancet Neurology, 2020
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)Neurological Sciences, 2020
- Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative ReviewAdvances in Therapy, 2020
- Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeuticsProgress in Neurology and Psychiatry, 2019
- Evaluation of Galcanezumab for the Prevention of Episodic MigraineJAMA Neurology, 2018